CN116390953A - 靶向人密蛋白18.2的抗体及其用途 - Google Patents
靶向人密蛋白18.2的抗体及其用途 Download PDFInfo
- Publication number
- CN116390953A CN116390953A CN202180067435.6A CN202180067435A CN116390953A CN 116390953 A CN116390953 A CN 116390953A CN 202180067435 A CN202180067435 A CN 202180067435A CN 116390953 A CN116390953 A CN 116390953A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- antigen
- amino acid
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/119648 | 2020-09-30 | ||
| CN2020119648 | 2020-09-30 | ||
| CNPCT/CN2021/072534 | 2021-01-18 | ||
| CN2021072534 | 2021-01-18 | ||
| PCT/CN2021/121585 WO2022068854A1 (en) | 2020-09-30 | 2021-09-29 | Antibodies targeting human claudin 18.2 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116390953A true CN116390953A (zh) | 2023-07-04 |
Family
ID=80949747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180067435.6A Pending CN116390953A (zh) | 2020-09-30 | 2021-09-29 | 靶向人密蛋白18.2的抗体及其用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240034784A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4222174A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023543493A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230078701A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116390953A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022068854A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026050213A1 (en) | 2024-08-27 | 2026-03-05 | Usbolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates and uses thereof |
| WO2026076388A1 (en) * | 2024-10-03 | 2026-04-09 | The Broad Institute, Inc. | Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109762067A (zh) * | 2019-01-17 | 2019-05-17 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| CN111234033A (zh) * | 2020-01-21 | 2020-06-05 | 南京北恒生物科技有限公司 | 多链嵌合抗原受体及其用途 |
| WO2020114480A1 (en) * | 2018-12-07 | 2020-06-11 | Zai Lab (Shanghai) Co., Ltd. | Anti-claudin antibodies and uses thereof |
| CN111434692A (zh) * | 2019-01-15 | 2020-07-21 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018006882A1 (zh) * | 2016-07-08 | 2018-01-11 | 科济生物医药(上海)有限公司 | 抗密蛋白18a2的抗体及其应用 |
| MX2019010156A (es) * | 2017-02-27 | 2020-01-09 | Dragonfly Therapeutics Inc | Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2. |
| CN110606891B (zh) * | 2018-06-17 | 2022-12-06 | 上海健信生物医药科技有限公司 | 一种针对人cldn18.2的抗体分子,抗原结合片段及其医药用途 |
| EP3824096A4 (en) * | 2018-07-18 | 2022-04-20 | AskGene Pharma Inc. | NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF |
-
2021
- 2021-09-29 EP EP21874509.9A patent/EP4222174A4/en active Pending
- 2021-09-29 JP JP2023519819A patent/JP2023543493A/ja active Pending
- 2021-09-29 US US18/245,114 patent/US20240034784A1/en active Pending
- 2021-09-29 CN CN202180067435.6A patent/CN116390953A/zh active Pending
- 2021-09-29 KR KR1020237012580A patent/KR20230078701A/ko active Pending
- 2021-09-29 WO PCT/CN2021/121585 patent/WO2022068854A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020114480A1 (en) * | 2018-12-07 | 2020-06-11 | Zai Lab (Shanghai) Co., Ltd. | Anti-claudin antibodies and uses thereof |
| CN111434692A (zh) * | 2019-01-15 | 2020-07-21 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
| CN109762067A (zh) * | 2019-01-17 | 2019-05-17 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| CN111234033A (zh) * | 2020-01-21 | 2020-06-05 | 南京北恒生物科技有限公司 | 多链嵌合抗原受体及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4222174A4 (en) | 2025-02-12 |
| US20240034784A1 (en) | 2024-02-01 |
| JP2023543493A (ja) | 2023-10-16 |
| WO2022068854A1 (en) | 2022-04-07 |
| EP4222174A1 (en) | 2023-08-09 |
| KR20230078701A (ko) | 2023-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7724332B2 (ja) | クローディン18.2結合部分およびその利用 | |
| US20250145718A1 (en) | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof | |
| CN107614529B (zh) | Pd-l1抗体、其抗原结合片段及其医药用途 | |
| KR20230097165A (ko) | 나노바디에 결합하는 trop2 및 이의 용도 | |
| US20240034784A1 (en) | Antibodies targeting human claudin 18.2 and uses thereof | |
| EP4249511A2 (en) | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof | |
| US20230080842A1 (en) | Tetravalent symmetric bispecific antibodies | |
| KR102967396B1 (ko) | Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용 | |
| CN118871468A (zh) | 一种新型免疫调节剂的开发和应用 | |
| JP7830621B2 (ja) | 抗-b7-h4/抗-4-1bb二重特異的抗体およびこれの用途 | |
| JP2024532886A (ja) | ヒトCD16aに対する抗体及びその変異体 | |
| TW202246341A (zh) | 針對NKp46的抗體及其應用 | |
| TW202611086A (zh) | 特異性結合Claudin 18.2的抗體及其製法和應用 | |
| CN111936516B (zh) | 新型抗egfr抗体多肽 | |
| CA3215704A1 (en) | Antibodies binding trop2 and uses thereof | |
| WO2022247826A1 (zh) | 靶向pd-l1和cd73的特异性结合蛋白 | |
| CN110272489A (zh) | 一种针对tim-3的全人源化抗体分子,抗原结合片段及其医药用途 | |
| US12590155B2 (en) | Molecules binding PD-L1 and uses thereof | |
| EP4613774A1 (en) | Single domain antibody targeting human ror1 | |
| TWI894360B (zh) | 抗tigit抗體及雙抗體和它們的應用 | |
| EP4585618A1 (en) | Anti-ilt4 antibody and pharmaceutical use thereof | |
| WO2019072274A1 (zh) | 一种激动型4-1bb单克隆抗体 | |
| WO2026077408A1 (zh) | 特异性结合ox40和/或il-13的抗原结合分子及其医药用途 | |
| EA047760B1 (ru) | Группы, связывающие клаудин 18.2, и их использование |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |